2001 Article Pharmacokinetics Phase I Studies Small Boron compounds Year 2001

Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin

Journal of Clinical Oncology, 2001

Authors:   M. Rosenthal,B. Kavar,J. Hill,D. Morgan,R. Nation,S. Stylli,R. Basser,S. Uren,H. Geldard,M. Green,S. Kahl,A. Kaye,
Journal: Journal of Clinical Oncology
Abstract: Purpose: To determine the recommended dose, toxicity profile, and pharmacokinetics of a novel boronated porphyrin (BOPP) for photodynamic therapy (PDT) of intracranial tumors. Patients and Methods: BOPP was administered alone in increasing doses (0.25, 0.5, 1.0, 2.0, 4.0, or 8.0 mg/kg) preoperatively in patients with intracranial tumors undergoing postresection PDT until dose-limiting toxicity (DLT) was observed. Results: Twenty-nine assessable patients with intracranial tumors received BOPP intravenously 24 hours before surgery. The recommended dose was 4 mg/kg. Dose escalation was limited by thrombocytopenia. The most common nonhematologic toxicity was skin photosensitivity. Pharmacokinetic parameters showed increased area under the plasma concentration-time curve and maximum concentration with increased dose. Tumor BOPP concentrations also increased with increased dose. Conclusion: BOPP at a dose of 4 mg/kg was well tolerated. DLT was thrombocytopenia, and photosensitivity was the only other toxicity of note. The efficacy of PDT using BOPP requires further exploration. © 2001 by American Society of Clinical Ontology.